ILIAS Biologics
Korea - DaejeonBiotechnology
Focus: ILIAS Biologics is a Korea-based biotechnology company focused on exosome therapeutics, a nascent modality with significant potential in drug delivery and regenerative medicine. Limited public data suggests early-stage positioning in a specialized therapeutic area.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Open Jobs
0
About ILIAS Biologics
AI assessmentNot HiringNo open roles listed right now. Follow ILIAS Biologics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ILB-202
HealthyClinical Trials (1)
NCT05843799A Study to Evaluate the Safety and Tolerability of ILB-202
Phase 1Help build intelligence for ILIAS Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.